Tag: Newsletter

Regulatory Watch News

• 

  Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees to Pay $3.6M to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl Product

  US Department of Justice

  May 9, 2025

  The Justice Department announced today that Assertio Therapeutics Inc., formerly known as Depomed Inc., (Assertio), a pharmaceutical company headquartered in Lake Forest, Illinois, has agreed to pay $3.6 million to resolve claims that Assertio violated the False Claims Act (FCA) by causing the submission of false claims for the transmucosal immediate-release fentanyl (TIRF) drug Lazanda for individuals who did not have breakthrough cancer pain.

• 

  Update to the UK Sanctions List: Russia Regime

  UK Government

  May 9, 2025

  Today, 9 May, the UK Government has sanctioned 101 ships, 5 individuals, and 4 entities under the Russia sanctions regime. This is the UK's largest package targeting Russia’s shadow fleet and its enablers.

• 

  Bruna Szego addresses the public for AMLA in Dublin

  AMLA

  May 9, 2025

  At the European Anti-Financial Crime Summit in Dublin, Ms. Bruna Szego, the inaugural Chair of the European Anti-Money Laundering Authority (AMLA), delivered a keynote speech, to an audience of public and private sector stakeholders, highlighting the Authority’s strategic priorities and the urgent need for unified, cross-sector action against financial crime. Ms. Szego underscored the transformative potential of AMLA, describing it as "a significant step ushering in a new chapter of enhanced cooperation and unified action in our shared mission to counter money laundering and terrorism financing."